ExPression Of IL-17A In PeriPheral Blood Of Non-small Cell Lung Cancer And Its RelationshiP With Bone Metastasis Of Adenocarcinoma

Objective:1.To investigate the expression level of interleukin-17 A in peripheral blood of patients with non-small cell lung cancer(NSCLC)in different clinicopathological features and analyze the correlation.2.To investigate the correlation between IL-17 A in peripheral blood of patients with lung adenocarcinoma and bone metastasis.Method:According to the exclusion criteria,83 newly treated patients diagnosed with NSCLC in the respiratory Department of the First Affiliated Hospital of Nanchang University from November 2021 to November 2022 were included in the experimental group,and 20 healthy patients in the physical examination center were included as the control group.Serum IL-17 A levels in NSCLC group and control group,as well as in lung adenocarcinoma patients with and without bone metastasis and healthy control group were determined by ELISA.(I)To explore the difference of IL-17 A level in clinicopathologic features in NSCLC patients.First,t test was used to compare IL-17 A levels between NSCLC patients and healthy control group.Secondly,t test and multivariate Logistic regression analysis were used to evaluate whether clinicopathologic features of NSCLC patients were independent influencing factors of IL-17 A elevation.(2)To explore the correlation analysis between IL-17 A in peripheral blood of patients with lung adenocarcinoma and bone metastasis.First,one-way variance test was used to compare IL-17 A levels in patients with metastatic lung adenocarcinoma,non-metastatic lung adenocarcinoma,and healthy lung adenocarcinoma.Secondly,univariate and multivariate Logistic regression analysis was used to evaluate whether IL-17 A was an independent influencing factor for NSCLC bone metastasis.Finally,the effective concentration of IL-17 A in differentiating lung cancer with bone metastasis,non-bone metastasis and healthy patients was studied by ROC curve analysis.Results SPSS statistical software was used for analysis.Results:1.The serum level of IL-17 A in NSCLC patients(23.67±9.26Pg/ml)was significantly higher than that in control group(10.12±2.83Pg/ml),and the difference was statistically significant.(P<0.05).2.The concentration of IL-17 A was closely correlated with smoking status,tumor differentiation,TNM stage(III,IV),lymph node metastasis,and pathogenesis(squamous cell carcinoma,adenocarcinoma)(P<0.05).The concentration of IL-17 A in smoking patients(28.43±8.43 Pg/ml)was higher than that in non-smoking patients(21.73±9.14Pg/ml).The difference was statistically significant(P<0.05): the level of IL17 A in stage IV patients(37.54±8.30Pg/ml)was significantly higher than that in stage III patients(28.21±9.54 Pg/ml),the difference was statistically significant(P<0.05): The lower the degree of tumor differentiation was,the higher the expression intensity of IL-17 A was.The level of IL-17 A in patients with high differentiation(25.27±8.74 Pg/ml)was significantly lower than that in patients with low differentiation(29.85±9.35 Pg/ml),and the difference was statistically significant(P<0.05).The level of IL-17 A in patients with lymph node metastasis(26.13±9.57Pg/ml)was significantly higher than that in patients without lymph node metastasis(21.27±9.31Pg/ml).The difference was statistically significant(P<0.05):The concentration of IL-17 A in squamous cell carcinoma patients(24.07±9.42Pg/ml)was higher than that in adenocarcinoma patients(21.35±8.37Pg/ml),and the difference was statistically significant(P<0.05).There was no significant association between IL-17 A serum concentration and patient sex and age,and the difference was not statistically significant.(P>0.05)。3.The degree of differentiation,clinical stage,lymph node metastasis and pathological type were all independent factors influencing the elevated serum expression level of IL17 A in patients with non-small cell lung cancer.4.The expression levels of IL-17 A in lung adenocarcinoma with bone metastasis group,lung adenocarcinoma without bone metastasis group and healthy control group were(31.31±9.49)Pg/m L,(22.87±9.63)Pg/m L and(10.12±2.84)Pg/m L,respectively.The differences among the three groups were statistically significant(F = 12.58,P <0.05).P < 0.05).5.The degree of tumor differentiation,clinical stage and serum IL-17 A concentration are independent risk factors for bone metastasis of lung adenocarcinoma.6.According to ROC curve analysis,the critical value of serum IL-17 A expression was 26.84Pg/ml,the sensitivity was 68.8%,the specificity was 78.9%,and the Youden index was 0.898 in the differential diagnosis between the bone metastasis group and non-bone metastasis group(AUC was 0.771,95%CI: The critical value of serum IL-17 A expression was 15.79Pg/ml,the sensitivity was 90.60%,the specificity was 100%,and the Youden index was 0.906(AUC was 0.980,95%CI,95%CI).0.951-1.000).Conclusion:1.Serum IL-17 A is highly expressed in patients with non-small cell lung cancer,and is correlated with smoking,pathological type,differentiation degree,PTNM stage,lymph node metastasis,and different pathological types.IL-17 A can be used as one of the serological markers for the diagnosis of NSCLC.2.Serum IL-17 A is an independent factor affecting the occurrence of bone metastases in NSCLC patients with adenocarcinoma,and is positively correlated with the risk of bone metastases,which provides a certain clinical basis for further research on the diagnosis and prognosis of bone metastases in NSCLC with IL-17 A.